Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study
Name: Almonertinib
Name: Pemetrexed
Name: Carboplatin
Description: progression free survival
Measure: PFS Time: from the first cycle of treatment (day one) to two month after the last cycle (each cycle is 21 days)Allocation: Randomized
Parallel Assignment
There is one SNP
Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study. --- T790M ---
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study PFS. --- T790M ---
After drug resistance, it was confirmed to be positive for EGFR T790M mutation by biopsy or free DNA test. --- T790M ---
Lung Cancer, Non-small Cell EGFR T790M EGFR Gene Mutation Lung Neoplasms Carcinoma, Non-Small-Cell Lung null --- T790M ---